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3’-IV-Aminoacyl analogs of puromycin with nonnatural aromatic amino acids were synthesized and their inhibitory activity in E. coli in vitro protein 
synthesizing system was evaluated. The analogs with L-2-naphthylalanine, L-p-biphenylalanine, L-2-anthrylalanine and trans+p-phenylazophenyla- 
lanine were found to inhibit the protein synthesis with high efficiency. The inhibition suggests that these nonnatural amino acids are accepted by 
the active center of the E. coli ribosomal A site. A model for the adaptability of nonnatural aromatic amino acids to the active center is proposed. 
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1. INTRODUCTION 
Until recently, the amino acid replacements in pro- 
teins are limited to 20 natural amino acids in the ordi- 
nary protein engineering. Recently, however, several 
groups reported techniques for the incorporation of 
nonnatural amino acids into proteins [l-3] by the use 
of chemically misacylated tRNAs [4,5]. By introducing 
nonnatural amino acids into biosynthetic proteins, the 
scope of protein engineering will be extended to include 
a wide variety of artificial functions. In protein biosyn- 
thesis, the selection of amino acids takes place essen- 
tially at the aminoacylation of tRNA under the control 
of aminoacyl tRNA synthetase. Therefore, once a 
tRNA is misacylated with a noncognate amino acid, the 
latter amino acid will be directly incorporated into pro- 
teins. This was actually shown by Noren et al. [2] and 
Bain et al. [3] However, they reported that the incorpo- 
ration efficiency depends sharply on the type of amino 
acids. For instance, D-phenylalanine was exclusively re- 
jected in their biosynthesizing system. This must be be- 
cause other steps such as the peptide bond formation in 
ribosome, discriminate nonnatural amino acids from 
natural ones. 
In this study, we evaluated the adaptability of non- 
natural amino acids carrying a variety of aromatic 
groups, to the A site of E. coli ribosomal peptidyl trans- 
ferase center. For this purpose, 3’-iV-aminoacyl analogs 
of puromycin with nonnatural amino acids (Compound I) 
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were used. Puromycin is an inhibitor of protein syn- 
thesis and known to bind to the ribosomal A site and 
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block the entry of aminoacyl tRNA. The amino group 
of bound puromycin forms a peptide bond with the 
carboxyl group of the peptidyl tRNA on the P site. The 
resulting peptide with a terminal puromycin moiety 
leaves the ribosome. The inhibitory activity of puromy- 
tin analogs has been examined as a measure for the 
adaptability of amino acids to the active center of ribo- 
somal A site. The analogs of aromatic amino acids, 
L-phenylalanine and L-tyrosine were most effective 
[6-81, and those with 0-benzyl+serine, S-benzyl-L- 
cysteine [7,8], L-homocitrulline [9] and L-lysine [lo] were 
moderately active, whereas the analogs of other amino 
acids were almost inactive. The optical configuration of 
the amino acids was also important since the D-phenyla- 
lanyl analog was far less active than the L-isomer [6]. 
We examined the inhibitory activity of puromycin 
analogs with nonnatural amino acids carrying large aro- 
matic groups (Fig. l), and predicted whether or not 
these nonnatural amino acids can be incorporated into 
proteins. 
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2. MATERIALS AND METHODS 3. RESULTS 
Puromycin, puromycin aminonucleoside, L-1-naphthylalanine (2) 
and r.-2naphthylalanine (3) were purchased from Sigma. L-l-pyren- 
ylalanine (4), L-2-pyrenylalanine (5), L-p-biphenylalanine (6), L-2-an- 
thrylalanine (7), L-2-anthraquinonylalanine (S), L-9-carbazolylalanine 
(9), r_-9-ethyl-3-carbazolylalanine (lo), t.-9-phenanthrylalanine (11) 
and t.-p-phenylazophenylalanine (12) were synthesized in our labora- 
tory [l 11. L-AzOC, (13-16)andrXarC, (17,18) weregifts fromprofes- 
sor Nishino of Kyushu Institute of Technology. 
The puromycin analogs were synthesized as follows: puromycin 
aminonucleoside (0.01 mmol), rer~-butyloxycarbonyl-protects ammo 
acid (0.01 mmol) and 1-hydroxy~nzotriazole hydrate (0.011 mmol) 
were dissolved in 0.1 ml of anhydrous dimethylformamide. To this 
solution, I-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.011 
mmol) was added at 0°C and the mixture was stirred for 2 h at 0°C 
and 22 h at room temperature. The mixture was diluted with 2 ml of 
ethyl acetate and washed twice with 4% NaHCO,, and twice with 
saturated NaCl. The organic phase was dried over MgSOd and the 
solvent was evaporated. The resulting solid was recrystallized from 
ethylacetate and n-hexane. For deprotection, the product was dis- 
solved in 0.1 ml of trifluoroacetic acid at O’C. After 30 min at O”C, 
the solvent was flushed off by Nz gas, then the deprotected product 
was washed with ether for several times and dried in vacua. The purity 
was confirmed by reverse-phase HPLC and ‘H-NMR. 
The results of the inhibition experiments are summa- 
rized in Table I. Puromycin and L-phenylalanyl analogs 
showed strong inhibitory activity as reported previously 
[6]. Similarly, the analogs of L-2-naphthylalanine, L-P- 
biphenylalanine, L-2-anthrylalanine, and L-p-phenyl- 
azophenylalanine were found to inhibit with good effi- 
ciency. On the other hand, the analog of L-l-naphthyl- 
alanine showed negligible inhibitory activity, in contrast 
to that of L-2-naphthylalanine. The analogs of L-l-py- 
renylalanine, t_-Zpyrenylalanine, L-9-phenan~rylalan- 
ine, L-2_anthraquinonylalanine, L-9carbazolylalanine 
and L-9-ethyl-3carbazolylalanine were also inactive. 
In the inhibition experiment, E. edi S-30 extract 1121, mRNA encod- 
ing bacteriophage T7 genelO, and ?Xabeled leucine were used. Pro- 
tein synthesis was carried out at 37°C for 30 min in the presence of 
various concentrations of puromycin analogs. The amount of the 
protein synthesized was measured by filter paper disk technique [13]. 
The inhibitory activity of the analogs of puromycin was expressed 
relative to a control experiment without inhibitor. 
The inhibitory activity was markedly decreased when 
the trans-azobenzene group of the p-phenylazophenyl- 
alanyl analog was photoisomerized to the c&form, as 
shown in Fig. 2. Irradiation with UV light at 350 nm 
resulted in conversion of about 80% of azobenzene 
group to the &-form under photostationary state. The 
inhibitory activity of the puromycin analog was low 
under this condition. The extrapolation to 100% cis- 
form showed that the analog with cam-~-phenylazophen- 
ylalanine was virtually inactive. 
The effect of spacer lengths between the C” atom and 
aromatic groups was also examined. In Table IB, the 
results of azobenzene derivatives and carbazole deriva- 
Table I 
Inhibitory activity of 3*-N-aminoacyl analog of puromycin with a variety of aromatic natural and nonnatural ammo acids in E.eoli in vitro protein 
synthesizing system 
Inhibition (%) 
Concentration (M) 
Amino acid 3 x lo+ 1 x10-3 3 x 1o‘4 1 x 10-4 3 x 10-5 1 x 1o-5 
A. 
O-Methyltyrosine 
Phenylalanine 
I-Naphthylalanine 
2-Naphthylalanine 
1 Pyrenylalanine 
2Pyrenylalanine 
~-Biphenylalanine 
9-Phenanth~l~anine 
2-~th~lalani~e 
2.~thraquinonylalanine 
9-Carbazolylalanine 
9.Ethyl-3-carbazolylalanine 
p_Phenylazophenylalanine 
B. 
Azoc, 
Azoc4 
Azoc, 
=, 
Care, 
CarC, 
_* 98.8 99.0 
91.3 98.9 98.3 
65.6 29.2 0 
99.2 90.0 92.3 
-** 29.0 4.5 
_** -** 0 
97.8 90.4 71.6 
83.4 62.1 28.6 
97.8 98.5 98.9 
58.1 33.0 34.6 
25.5 5.7 7.1 
0.8 11.0 4.4 
96.8 99.0 91.3 
_* 99.9 
97.8 96.5 
_** 15.3 
_** 16.2 
34.6 11.5 
1.9 0 
89.6 
79.7 
a.7 
13.7 
0 
99.0 98.5 80.6 
94.4 96.2 70.1 
93.9 
0 
64.5 
0 
95.5 
0 
0 
0 
67.3 
37.8 
64.5 
0 
0 
74.6 
55.4 
81.2 
59.4 32.7 
14.1 
33.8 
28.4 
56.3 
73.0 
8.1 
0 
*Not tested. 
**Insoluble. 
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Fig. 1. Structure of aromatic natural and nonnatural amino acids used 
in this study. 
tives are shown. The azobenzene derivatives having 
short spacers were active but those having long spacers 
were inactive. The carbazole derivatives were found to 
be inactive in every case. 
4. DISCUSSION 
The results in Table I show that the inhibitory activ- 
ities of the puromycin analogs are widely different. The 
analogs are clearly divided into two groups depending 
on the inhibitory activity, those that show high activity 
at 10m5 M and those that show low activity even at 
1O-3 M. 
The analogs of high inhibitory activity may bind to 
the active center and form peptidyl puromycin, as has 
been demonstrated previously for the phenylalanine an- 
alogs, tyrosine, O-benzylserine, and S-benzylcysteine. 
The puromycin analogs of those amino acids inhibited 
the protein synthesis and formed peptidyl puromycin in 
the ribosome [7,8]. On the other hand, those of low 
activity may either have low affinity for the active cen- 
ter, or effectively bind to the active center but do not 
Concentlation (M) 
Fig. 2. Inhibitory activity of the puromycin analogs with L-p-phenyla- 
zophenylalanine: (o), rruns-form (before irradiation); (A), 80% 
c&form (after irradiation at 3.50 nm for 5 min); (0). 100% &form 
(extrapolated values); (0), puromycin as a reference. 
react with peptidyl tRNA. If the latter is the case, how- 
ever, a constant inhibitory efficiency that is lower than 
100% will be observed after all the binding sites were 
occupied by the addition of an excess amount of the 
puromycin analog. The results in Table I exclude this 
possibility, because the inhibitory activity of each ana- 
log is not constant over the concentration range of 
10-4-10-3 M and is increasing with the concentration. 
The concentration dependence in Table I shows that the 
low activities are due to low affinity for the active cen- 
ter. Therefore, it is concluded that L-2_naphthylalanine, 
L-p-biphenylalanine, L-2-anthrylalanine, trans-bp- 
phenylazophenylalanine, AzOC, and AzOC, adapt to 
the active center of ribosomal A site, but L-l-naphthyl- 
alanine, L- 1 -pyrenylalanine, L-Zpyrenylalanine, L-2-an- 
thraquinonylalanine, L-9-carbazolylalanine, L-9-ethyl- 
3carbazolylalanine, L-9_phenanthrylalanine, cis-L-p- 
I 
N” 
P-SITE 
Fig. 3. A model for the adaptability of nonnatural aromatic amino 
acids to the active center of E. coli ribosomal A site. The 3’-N-ami- 
noacyl analog of puromycin and peptidyl tRNA exist in ribosomal A 
site and P site, respectively. Nonnatural amino acids carrying benzene 
rings in regions B, E, G, H and I can adapt to the active center of A 
site, whereas those carrying benzene rings in other regions do not 
adapt. 
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phenylazophenylalanine, AzOQ, AzOC,, CarC, and 
CarC, do not adapt. 
The next question was why some nonnatural amino 
acids adapt to the active center but others do not. In 
previous studies, the analogs with aromatic amino acids 
containing one benzene ring have been found to adapt 
to the active center [Ml. However, the adaptability 
does not depend only on the size of aromatic group, 
because 2-naphthylalanine adapts but 1 -naphthylalan- 
ine does not. Therefore, the active center may discrimi- 
nate nonnatural amino acids not only by their size but 
their geometry. From a consideration of the results in 
Table IA, a simple model for the adaptability of aro- 
matic nonnatural amino acids to the active center can 
be proposed as shown in Fig. 3. The benzene rings of 
arylalanine-type amino acids denoted as A, B, C, etc., 
can be divided into allowed regions (B, E, G, H, I) and 
disallowed regions (A, C, D, F). The amino acids that 
adapt to the active center contain benzene rings only in 
the allowed regions. On the other hand, those that do 
not adapt contain benzene rings in the disallowed re- 
gions. 
Based on this model, nonnatural amino acids that 
adapt to the active center can be predicted. For exam- 
ple, L-2-phenanthrylalanine that occupies regions B, E 
and H may adapt, whereas L-1-phenanthrylalanine that 
occupies regions A, B and D will not. This model 
explains that the analogs with benzyl derivatives of 
L-serine and L-cysteine are active [7,8], because the ben- 
zene rings of these derivatives are located in region E. 
The present results predict what type of nonnatural 
amino acids can be incorporated into proteins when 
they are attached to tRNA and added to the in vitro 
protein biosynthesizing system [l-3]. In the case of 
naphthylalanine, for instance, L-2-naphthylalanine may 
be incorporated into proteins but L- 1 -naphthylalanine 
may not. Similarly, L-2-phenanthrylalanine is a proper 
amino acid for the incorporation of phenanthryl group. 
The results in Table IB suggest hat spacer length is 
also an important factor in determining the adaptabil- 
ity. In the case of the azobenzene derivatives, spacers 
with IZ 2 5 are clearly unfavorable, suggesting that 
azobenzene groups very remote from C” atom do not 
adapt to the ribosomal A site. In the case of carbazole 
derivatives, however, no proper spacer length was 
found for the incorporation of 9-substituted carbazole 
group. 
The incorporation of the photofunctional nonnatural 
amino acids into proteins is now in progress, and will 
appear in future reports. 
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